ST. LOUIS--(BUSINESS WIRE)--Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced the appointment of Don Hardison to the Company’s strategic advisory board.
Don brings more than 40 years of executive leadership experience in both emerging and Fortune 500 companies to Geneoscopy’s advisory board. Most recently, Don served as President and CEO of Biotheranostics up until its acquisition by Hologic in February 2021. Prior to that, Don was President, CEO and Director at Good Start Genetics. Don also served as President and CEO of Exact Sciences, where he helped oversee the company’s initial public offering. Don has also held multiple senior leadership positions at companies such as LabCorp, Quest Diagnostics, and SmithKline Beecham, where he built a strong track record in strategy development, team building, and market planning and execution.
“I am optimistic that once approved by the FDA, Geneoscopy’s stool RNA platform will provide the opportunity to deliver an industry-leading accuracy profile for CRC screening, driven by high sensitivity for precancerous adenomas,” said Mr. Hardison. “This could enable Geneoscopy’s test to serve as a much-needed aid in the prevention of colorectal cancer. I am incredibly excited to help bring this potentially transformational CRC screening product to market and to assist Geneoscopy with its broad pipeline of diagnostic products for other GI health indications with major unmet clinical needs.”
Andrew Barnell, CEO of Geneoscopy, added, “Given Don’s extensive experience in diagnostic laboratory management, commercialization, sales, marketing, strategy, and operations, we’re excited to have him join our strategic advisory board at such an important stage in our company’s journey.”
About Geneoscopy Inc.
Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Indicative of its breakthrough status, preliminary trials suggest that the diagnostic can detect these lesions at a higher rate than all existing noninvasive screening tests.
Web | https://www.geneoscopy.com/
Twitter | http://www.twitter.com/geneoscopyco
Facebook | https://www.facebook.com/GeneoscopyCo
LinkedIn | https://www.linkedin.com/company/geneoscopy
Geneoscopy Inc. Forward-Looking Statements
The information contained in this release includes information about Geneoscopy’s future plans concerning its noninvasive molecular test that can detect colorectal cancer and precancerous adenomas, and as such constitute forward-looking statements. These forward-looking statements are based upon the Company’s reasonable estimates of future results or trends. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Geneoscopy’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Although the Company believes that its business plans and objectives reflected in or suggested by these forward-looking statements are reasonable, such plans or objectives may not be achieved and the actual results may differ substantially from the projected results.
